|
BRCA tumor test in ovarian cancers: The changing role of molecular pathology in the era of PARP inhibitor (PARPi) therapy. |
|
|
Consulting or Advisory Role - Roche |
Travel, Accommodations, Expenses - Novartis |
|
|
Honoraria - AstraZeneca; Biocartis; MSD; Roche; Thermofisher Scientific Biomarkers |
Travel, Accommodations, Expenses - AstraZeneca; Biocartis; Illumina; MSD; Roche; Thermo Fisher Scientific |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - MSD Oncology; Pfizer |
Consulting or Advisory Role - Astellas Pharma; Dako; Novartis; Roche/Genentech |
Research Funding - Dako/Agilent Technologies (Inst); Roche/Genentech; Ventana Medical Systems (Inst) |
Travel, Accommodations, Expenses - Celgene; Roche; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; PharmaMar; Roche/Genentech; Tesaro |
Consulting or Advisory Role - AstraZeneca; BioCad; Clovis Oncology; MSD Oncology; Pfizer; PharmaMar; Roche/Genentech; Takeda; Tesaro |
|
|
No Relationships to Disclose |